A teenager walks into a local clinic in Spain with anxiety, low mood, or a feeling that life is becoming too much. Increasingly, that visit is more likely to end with medication than it was only a few years ago.
A new analysis of 157,868 primary care diagnoses among patients ages 14 to 25, described by Xavier Martínez-Mendía and Maite Campo-Iparagirre, researchers connected with OPIK at the University of the Basque Country, found that the chance of receiving an anxiolytic, hypnosedative, or antidepressant within 30 days rose from 24.4% in 2018 to 35.1% in 2024.
The finding does not mean every prescription was wrongly handed out. It asks a sharper question, are health systems treating youth distress too quickly as a chemical problem?
Same diagnosis, more pills
The key point is not only that more young people are seeking help. It is that, after similar diagnoses of anxiety or depression, the medical response appears to have become more pharmaceutical.
Psychotropic drugs are medicines that affect mood, sleep, anxiety, or behavior. Anxiolytics are used to calm anxiety, antidepressants can treat depression and some anxiety disorders, and hypnosedatives are usually used to help people sleep or feel sedated.
That shift matters because adolescence and early adulthood are not quiet years. They are years of school pressure, first jobs, family tension, social media noise, and uncertainty about the future.
What medicalization means
Medicalization of distress is a simple idea with a complicated effect. It means that sadness, stress, uncertainty, grief, or frustration start to be understood mainly as clinical symptoms that need a medical fix.
That does not mean those feelings are fake–it’s quite the opposite. The worry is that a pill may quiet the symptom while leaving the pressure underneath untouched.
Related research in Gaceta Sanitaria has described how mental health diagnoses and prescribed psychotropic use can be analyzed alongside gender, visits to primary care, and social class.
That matters here, because many young people are not just dealing with brain chemistry. They are dealing with real-life conditions that can make distress harder to escape.
Why the fast fix happens
Primary care is the front door for many families. It is where a teen might mention panic before an exam, months of poor sleep, or a sadness that has started to affect school.
The visit is often short, though. When waiting lists for psychological care are long, the prescription pad can become the quickest tool in the room. Not the perfect tool, just the available one.
There is also the everyday pull of urgency. We are used to one-click answers, same-day deliveries, and instant messages. So when emotional pain shows up, families may understandably want relief now.
Why experts are cautious
Medication can be necessary, especially when symptoms are severe, persistent, or dangerous. No serious mental health debate should pretend that antidepressants or anxiety medication never help.
The caution is about first responses. Spain’s GuíaSalud recommendations say antidepressants are not recommended as initial treatment for mild depression in children and adolescents, and psychological treatment is recommended first in several moderate cases.
When medication is used, guidance calls for information, monitoring, and attention to possible side effects.
That is a slower road. It may involve therapy, family support, school changes, better sleep, safer routines, and follow-up. For a young person, though, those pieces can matter as much as the prescription itself.
Spain’s wider pressure
The Spanish Society of Family and Community Medicine has already warned that youth mental health is a growing challenge in primary care.
In 2024, it cited figures showing that 59% of Spaniards ages 15 to 29 reported mental health problems, while two in 10 people ages 14 to 18 had used benzodiazepines, a group of sedative drugs often prescribed for anxiety or sleep.
Those numbers help explain why doctors are under pressure. They also show why the debate cannot be reduced to blaming young people, parents, or physicians.
Spain’s Ministry of Health 2025 to 2027 mental health action plan points in a broader direction, with goals on community care, safe psychotropic use, better prescribing, and deprescribing when it is appropriate.
In practical terms, the system is being asked to offer more than medication when a patient’s problem is partly social, emotional, or developmental.
What changes next
The study’s quiet message is that access matters. When therapy is hard to get, when schools are stretched, and when families are exhausted, the health system may end up treating distress through the fastest door.
A better approach would not shame medication or romanticize suffering. It would ask what kind of help each young person needs, and whether a prescription is a bridge, a last resort, or simply the only thing available that day.
For families, the takeaway is awkward but useful: a pill can reduce symptoms, yet it cannot rewrite academic pressure, loneliness, housing insecurity, or family conflict. Sometimes the first question should be less “which medication” and more “what support is missing?”
The main work has been presented at the annual meeting of the Spanish Society of Epidemiology.
